# A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

> **NCT00411034** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 463 (actual)

## Conditions studied

- Analgesics, Opioid
- Pain

## Interventions

- **DRUG:** OROS Hydromorphone HCI

## Key facts

- **NCT ID:** NCT00411034
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1999-09
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411034, "A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00411034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*